Intravenous Immunoglobulin Global Market Report 2024

The global intravenous immunoglobulin market has grown strongly in recent years. It will grow from $13.82 billion in 2023 to $14.84 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historical period can be credited to advancements in treating primary immunodeficiency disorders and neurological conditions, a growing elderly population, improved plasma fractionation techniques, widened applications in neurology, treatments for infectious diseases, and pediatric immunodeficiency therapies.

The global intravenous immunoglobulin market is expected to see strong growth in the next few years. It will grow to $20.24 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the upcoming period is driven by the escalating occurrence of autoimmune disorders, continuous advancements in immunology research, higher healthcare spending, the rise in cancer cases, innovative developments in immunoglobulin products, and the adoption of personalized medicine strategies. Key trends expected in the forecast period encompass the treatment of primary immunodeficiency disorders (PIDD), swift technological progress, strategic partnerships and collaborations, enhancements in manufacturing techniques, expanded applications in neurology and hematology, and progressions in immunotherapy.

The advancing segment of the elderly population stands poised to propel the intravenous immunoglobulin market. As individuals surpass 65 years, their immune systems often falter, necessitating supplemental immunoglobulins due to declining antibody production. This surge in demand is evident, exemplified by projections in India where the elderly count surged from 138 million in 2021 to an anticipated 194 million by 2031. Likewise, the World Health Organization anticipates a global rise, estimating 1.4 billion people above 60 years by 2030, a significant climb from 1 billion in 2020. This demographic shift distinctly augments the intravenous immunoglobulin market.

The escalating prevalence of rheumatoid arthritis (RA) forecasts substantial growth in the intravenous immunoglobulin (IVIG) market. RA, a chronic autoimmune ailment impacting joints, triggers inflammation and potential joint deterioration. IVIG, derived from healthy donors, presents a remedy by obstructing the inflammatory process in RA. Illustratively, estimations from the Australian Institute of Health and Welfare in June 2023 project 456,000 Australians afflicted by RA, constituting 2.0% of the total disease burden and 16% of musculoskeletal conditions in 2022. Similarly, data from the National Rheumatoid Arthritis Society in July 2022 indicates over 450,000 individuals in the UK grappling with RA. The rising prevalence of RA delineates a significant driver for the IVIG market.

Product innovation emerges as a pivotal trend shaping the intravenous immunoglobulin market landscape. Key market players prioritize novel offerings, exemplified by Octapharma's June 2021 announcement of 'Octagam 10%,' a pioneering human plasma-derived IVIg endorsed by the European Union for treating dermatomyositis in adults. This breakthrough addresses a rare autoimmune disorder, marking a stride in therapeutic advancement and improved patient outcomes.

Strategic focus on pioneering products like PANZYGA characterizes major companies in the intravenous immunoglobulin market. Notably, in February 2021, Pfizer Inc. achieved FDA approval for PANZYGA, specifically for adults combating chronic inflammatory demyelinating polyneuropathy (CIDP). This marked the first FDA-endorsed IVIG with dual maintenance dosing options, catering to the diverse needs of CIDP patients. Grounded on comprehensive Phase 3 trials involving 142 individuals, this milestone offers healthcare providers flexibility in selecting appropriate dosages, addressing an unmet medical need in CIDP treatment.

In March 2021, Grifols SA, a leading Spanish pharmaceutical and chemical manufacturer, finalized the acquisition of GigaGen Inc for $115 million. This acquisition occurred in two phases such as initially, Grifols secured a 44% ownership for $35 million, followed by the acquisition of the remaining 56% stake for $80 million. This strategic move aligns with Grifols’ overarching R+D+I (research, development, and innovation) strategy, aimed at fostering innovation and conducting research that complements its core business operations. GigaGen, a biotechnology firm based in the United States, specializes in pioneering the development and discovery of recombinant biotherapeutic medications.

Major companies operating in the intravenous immunoglobulin market report are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bayer AG, LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., Emergent BioSolutions Inc., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

North America was the largest region in the intravenous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key categories of intravenous immunoglobulins encompass IgG, IgM, IgA, IgE, and IgD. IgG, the prevalent immunoglobulin in bodily fluids, plays a pivotal role in safeguarding against bacterial and viral infections. Its application involves reinforcing the body's innate defense mechanisms. These products find distribution channels across hospital and retail pharmacies, serving various medical needs like hypogammaglobulinemia, CIDP, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, among others. The end-users span hospitals, clinics, and home care setups.

This report provides intravenous immunoglobulin market statistics, including intravenous immunoglobulin industry global market size, regional shares, competitors with an intravenous immunoglobulin market share, detailed intravenous immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. This intravenous immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.